Men's Health

Philippe E. Spiess, MD, MS, presents the take home messages on penile, testis, and urethral cancer from the AUA annual meeting in Orlando, FL.

Landon Trost, MD, presents the take home messages on sexual function/dysfunction from the AUA annual meeting in Orlando, FL, including studies of clostridium collagenase histolyticum (CCH [XIAFLEX]).

Manish A. Vira, MD, presents the take home messages on minimally invasive surgery from the AUA annual meeting in Orlando, FL.

Richard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.

Jesse D. Sammon, DO, presents the take home messages on outcomes analysis from the AUA annual meeting in Orlando, FL.

K.C. Balaji, MD, presents the take home messages on basic science research from the AUA annual meeting in Orlando, FL.

Tobias S. Köhler, MD, MPH, presents the take home messages on infertility/andrology from the AUA annual meeting in Orlando, FL.

Michael C. Gong, MD, PhD, presents the take home messages on prostate cancer from the AUA annual meeting in Orlando, FL, including new findings about enzalutamide (XTANDI).

I consider urology to be a very unique field, one that I am lucky to be part of. Recently, though, I have begun to wonder whether the medical community (not necessarily the urology community) has been too quick to embrace the widespread use of testosterone replacement therapy.

New urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus

A recent large study has found no increased risk of heart attack in men undergoing testosterone replacement therapy.

Robot-assisted radical prostatectomy may be associated with improved surgical margin status compared to open radical prostatectomy for men with intermediate-risk and high-risk prostate cancer, according to a study presented at the AUA annual meeting in Orlando, FL.

Men with prostate cancer who are treated with external beam radiation therapy are at an increased risk for cancer of the bladder and rectum 10 years or more after their prostate cancer diagnosis, according to an analysis using data from the Surveillance, Epidemiology, and End Results program.

The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.

Salvage extended pelvic lymph node dissection (ePLND) may be highly beneficial for selected prostate cancer patients with biochemical recurrence and clinically recurrent nodal disease, say German researchers.

Shared decision making occurs in only one-third of men who have made a decision about prostate cancer screening, according to findings from a new study that one leading prostate cancer expert said were not at all surprising.

Testosterone replacement therapy is in the news again, for reasons both good and bad.

Results of a validation study confirm that cell cycle progression score provided by a commercially available genomic test (Prolaris) is a strong and independent outcome predictor in men with conservatively managed, clinically localized prostate cancer.

Two years ago in May, the U.S. Preventive Services Task Force recommended against PSA-based screening for prostate cancer, asserting that “many men are harmed as a result of prostate cancer screening and few, if any, benefit.”

New products and services from TERUMO Medical Corp., TOLMAR Pharmaceuticals, Spry Publishing, and Beckman Coulter Diagnostics.

Inappropriate use of a gonadotropin-releasing hormone agonist for androgen deprivation therapy of localized prostate cancer fell dramatically following implementation of reimbursement cuts mandated by the Medicare Modernization Act of 2003, but overuse remains problematic, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.

The FDA has approved a new testosterone gel formulation, marking the agency’s second approval of a testosterone replacement therapy in the course of a week.

The FDA has approved a nasal gel for men with hypogonadism and has granted clearance to a treatment for urinary incontinence in men. Separately, two drug makers are approaching the agency about regulatory approval for an over-the-counter version of a phosphodiesterase-type-5 inhibitor.

Results from the phase III PREVAIL trial of the oral androgen receptor inhibitor enzalutamide (XTANDI) have been published online in the New England Journal of Medicine (June 1, 2014).

A new study showing a survival benefit of more than 1 year with a chemotherapy-hormonal therapy combination given prior to castration resistance is being hailed by the study’s first author as a “new standard” of treatment for certain men with metastatic, hormone-sensitive prostate cancer.